Monocytes from mobilized stem cells inhibit T cell function

被引:57
作者
Ino, K [1 ]
Singh, RK [1 ]
Talmadge, JE [1 ]
机构
[1] UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198
关键词
transplantation; peripheral blood stem cell transplantation; apoptosis;
D O I
10.1002/jlb.61.5.583
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Granulocyte-macrophage colony-stimulating factor, mobilized peripheral blood stem cell (PSC) products, and peripheral blood leukocytes posttransplantation contain cells that cause allogeneic and autologous T cell apoptosis, Isolation and characterization of these cells demonstrated that they were low-density (Percoll fractionation) CD14(+) monocytes. T cells in PSC products have a depressed phytohemagglutinin (PHA) mitogenic response; however, purified CD4(+) or CD8(+) T cells exhibit a statistically normal mitogenic function, Furthermore, no T cell inhibitory activity was observed in CD14(+), CD4(+), and CD8(+) cell-depleted fractions enriched in CD4(-)CD8(-)TCR alpha/beta(+) T cells, Inhibition of T cell function by CD14(+) monocytes required cell-cell contact, and the analyses of DNA fragmentation by Southern and TUNEL analysis demonstrates an activation-induced T cell apoptosis in the presence of CD14(+) monocytes. Reverse-transcriptase polymerase chain reaction studies suggested that high levels of interleukin-10 or tumor necrosis factor gene transcripts in the PSC products may contribute to the inhibition of T cell function.
引用
收藏
页码:583 / 591
页数:9
相关论文
共 40 条
[1]  
AZEVEDO WM, 1995, BONE MARROW TRANSPL, V16, P647
[2]  
FARINAS MC, 1991, CANCER, V68, P1279, DOI 10.1002/1097-0142(19910915)68:6<1279::AID-CNCR2820680617>3.0.CO
[3]  
2-Y
[4]  
HENON PR, 1992, BONE MARROW TRANSPL, V9, P285
[5]  
HERTELWULFF B, 1988, J IMMUNOL, V140, P2633
[6]  
KESSINGER A, 1991, BLOOD, V77, P2322
[7]  
KIESEL S, 1989, TRANSPLANT P, V21, P3084
[8]  
Klingemann H G, 1995, J Hematother, V4, P261, DOI 10.1089/scd.1.1995.4.261
[9]   ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION FOR REFRACTORY LEUKEMIA AND LYMPHOMA - POTENTIAL ADVANTAGE OF BLOOD OVER MARROW ALLOGRAFTS [J].
KORBLING, M ;
PRZEPIORKA, D ;
HUH, YO ;
ENGEL, H ;
VANBESIEN, K ;
GIRALT, S ;
ANDERSSON, B ;
KLEINE, HD ;
SEONG, D ;
DEISSEROTH, AB ;
ANDREEFF, M ;
CHAMPLIN, R .
BLOOD, 1995, 85 (06) :1659-1665
[10]   COMPARISON OF PERIPHERAL-BLOOD STEM-CELL AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOMA PATIENTS - A CASE-CONTROLLED ANALYSIS OF THE EBMT REGISTRY DATA [J].
LIBERTI, G ;
PEARCE, R ;
TAGHIPOUR, G ;
MAJOLINO, I ;
GOLDSTONE, AH .
ANNALS OF ONCOLOGY, 1994, 5 :S151-S153